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The main hallmark of diabetic nephropathy is elevation in
urinary albumin excretion. We performed a genome-wide
linkage scan in 63 extended families with multiple members
with type II diabetes. Urinary albumin excretion, measured as
the albumin-to-creatinine ratio (ACR), was determined in 426
diabetic and 431 nondiabetic relatives who were genotyped
for 383 markers. The data were analyzed using variance
components linkage analysis. Heritability (h2) of ACR was
significant in diabetic (h2¼ 0.23, P¼ 0.0007), and nondiabetic
(h2¼ 0.39, P¼ 0.0001) relatives. There was no significant
difference in genetic variance of ACR between diabetic and
nondiabetic relatives (P¼ 0.16), and the genetic correlation
(rG¼ 0.64) for ACR between these two groups was not
different from 1 (P¼ 0.12). These results suggested that
similar genes contribute to variation in ACR in diabetic and
nondiabetic relatives. This hypothesis was supported further
by the linkage results. Support for linkage to ACR was
suggestive in diabetic relatives and became significant in all
relatives for chromosome 22q (logarithm of odds, LOD¼ 3.7)
and chromosome 7q (LOD¼ 3.1). When analyses were
restricted to 59 Caucasian families, support for linkage in all
relatives increased and became significant for 5q (LOD¼ 3.4).
In conclusion, genes on chromosomes 22q, 5q and 7q may
contribute to variation in urinary albumin excretion in
diabetic and nondiabetic individuals.
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Elevated urinary albumin excretion in the range of micro-
albuminuria or proteinuria is the hallmark of diabetic
nephropathy.1,2 Research during the last decade established
that the quantity of albumin excreted in the urine clusters
within families, regardless of whether the families were
ascertained through individuals with diabetes or without.3–6
Familial aggregation of a characteristic so closely related to
nephropathy justifies a whole genome scan in search of the
chromosomal regions harboring the genes (quantitative
trait loci, QTLs) controlling variation in urinary albumin
excretion.
Previously, we demonstrated that, if the urinary albumin
excretion in family members with diabetes is in the range of
microalbuminuria and proteinuria, the urinary albumin
excretion in family members without diabetes is also
elevated, although an order of magnitude lower (Figure 2
in Fogarty et al.7). This agrees with earlier findings in nuclear
families that the nondiabetic siblings and offspring of
probands with diabetes and proteinuria excrete more urinary
albumin than a general population without diabetes.8,9
Further, diabetic siblings of diabetic probands with protein-
uria have a greater risk of proteinuria than diabetic siblings of
probands with diabetes and normoalbuminuria in type 110–13
and type II diabetes.14,15
These results suggest a hypothesis that genetic predisposi-
tion to nephropathy is reflected in the level of urinary
albumin excretion. In the absence of diabetes, the level is in
the upper range of normoalbuminuria or lower range of
microalbuminuria. With exposure to diabetes, high-normal
levels of urinary albumin excretion worsen to microalbumi-
nuria and overt proteinuria.16 An implication of this
hypothesis is that variation in the quantity of albumin
excreted in the urine is controlled by the same QTLs in
diabetic and nondiabetic individuals.
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The current study aimed to identify chromosomal regions
containing QTLs that control variation in urinary albumin
excretion in 63 extended families. Ascertainment of families
was based solely on the availability of many members with
type II diabetes and many without.4,17 The search for these
QTLs employed a genetic linkage strategy that combined the
use of highly polymorphic markers with pedigree-based
multipoint variance component analysis.
RESULTS
The study group consists of 63 extended families with an
average of 6.8 diabetic members (range 2–14) and 6.8
nondiabetic members (range 1–18) per family. The clinical
characteristics of family members at the time of examination
are provided in Table 1 according to diabetes status (426 with
and 431 without diabetes). For those with diabetes, age was
57715 years and diabetes duration 11711 years (age at
diagnosis of diabetes, 46716 years), whereas the age of those
without diabetes was 46717 years. Treatment for diabetes
was insulin for 39%, oral agents for 34% and diet or no
treatment for 27%. Those with diabetes were more obese
than those without diabetes, and they had higher mean
arterial blood pressure (MAP) and were more frequently
treated with antihypertensive medications than those without
diabetes. End-stage renal disease (ESRD) had developed in 11
diabetic family members.
Albumin-to-creatinine ratio (ACR) levels were higher in
family members with diabetes than in those without. While
high values occurred in both groups, an ACR greater than
20 mg/mg was significantly more frequent in those with
diabetes than those without (41 vs 10%, Po0.001). Because of
the skewness of the ACR distribution, ACR was transformed
for analysis to log10 and multiplied by 10 (logACR in Table 1).
The distribution of relative pairs in this study according to
genetic relationship and diabetes status is shown in Table 2.
The 63 extended families generated 5656 relative pairs: 1332
relative pairs concordant for diabetes (diabetes mellitus
(DM)–DM pairs); 1849 relative pairs concordant for the
absence of diabetes (non-diabetes mellitus (NDM)–NDM pairs)
and 2475 relative pairs discordant for diabetes (i.e., one of the
pair had diabetes and the other did not, DM–NDM pairs).
Estimates of the heritability of residual (adjusted) logACR
were as follows: in relatives with diabetes, h2¼ 0.2370.08
(P¼ 0.0007 with 16% of the total phenotypic variance
explained by covariates); in relatives without diabetes,
h2¼ 0.3970.11 (P¼ 0.0001 with 5% of the total phenotypic
variance explained by covariates) and in all family members
together, h2¼ 0.2070.05 (P¼ 3 107 with 26% of the total
phenotypic variance explained by covariates).
As the main focus of this study was to identify QTLs for
logACR in individuals with diabetes, multipoint variance
component linkage analyses were conducted first in the 1332
DM–DM relative pairs, and then in all 5656 pairs of relatives
(DM–DM, NDM–NDM and DM–NDM pairs). Comparison
of the support for linkage coming from these two analyses
at a chromosomal region of interest is a measure of the
specificity of the effect of that region on variation in adjusted
logACR. Three possibilities were considered: (1) the effect
may be specific to relatives with diabetes if linkage is
supported in DM–DM pairs and decreases or remains
constant in all pairs; (2) the effect may be independent of
diabetes status if linkage support is present in DM–DM pairs
and increases significantly in all pairs and (3) the effect may
be specific to nondiabetic relatives if there is no linkage
support in DM–DM pairs but it is present in all pairs.
The number of chromosomal regions with potential
evidence for linkage (logarithm of odds, LODX1.2) was six
Table 1 | Clinical characteristics of the examined members of
the 63 families according to diabetes status
DM
Characteristics
Presenta
(N=426)
Absent
(N=431)
Men (%) 43 45
Age at examination (years) (mean7s.d.) 57715 46717
Age at diagnosis of diabetes (years) (mean7s.d.) 46716 –
Diabetes duration (years) (mean7s.d.) 11711 –
Hypoglycemic Rx at examination (%)
Insulin 39 –
Oral agents only 34 –
Diet only or no Rx 27 –
% ideal body weight (mean7s.d.) 140733 127726
Mean arterial BP (mmHg) (mean7s.d.) 98711 92713
Antihypertensive Rx (%) 45 14
Treatment with ACE inhibitors (%) 13 3
End-stage renal disease (%) 2.6 0.0
Urinary ACRb percentiles (mg/mg)
25th 6 4
50th 14 6
75th 55 9
90th 791 19
LogACRc (mean7s.d.) 13.978.4 8.173.8
aIncludes 44 individuals with impaired glucose tolerance and seven with gestational
diabetes.
bACR=albumin (mg) to creatinine (mg) ratio.
cLogACR=ACR transformed to the log10 and multiplied by 10. The distribution of
logACR in individuals with diabetes and without in the Joslin Family Collection was
published previously by Fogarty et al.7
Table 2 | Number of pairs of relatives in the 63 families
according to genetic relationship and diabetes status
Pairs of relatives by diabetes status
Relationship DM–DM NDM–NDM DM–NDM All pairs
Parental (0.500) 148 145 302 595
Sibling (0.500) 407 243 302 952
Half-sibling (0.250) 14 13 25 52
Grandparental (0.250) 18 19 31 68
Avuncular (0.250) 328 292 749 1369
Cousin, etc. (0.125) 244 607 561 1412
Other (0.063) 173 530 505 1208
All pairs 1332 1849 2475 5656
( ) Relationship coefficient; DM=individual with diabetes; NDM=individual without
diabetes.
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in DM–DM pairs and ten in all pairs (Figure 1). In the latter
analysis, with the greatly increased number of relative pairs,
the linkage support at the six regions identified in DM–DM
pairs changed as follows: the support for linkage (nominal
LOD) increased in three regions, becoming strong on 22q
(1.9 became 3.7) and 7q (2.2 became 3.1) and suggestive on
5q (1.2 became 2.6). The LOD increased slightly on 17p (1.5
became 1.6), decreased slightly on 21p (2.5 became 2.1) and
decreased below the potential linkage range for the second
region on 5q (1.5 became 0.5). The nominal LOD in five new
regions with potential evidence for linkage included 16p (0.8
became 2.0) and four others: chromosomes 2p (0.8 became
1.4), 6p (0.5 became 1.6), 6q (0.6 became 1.6) and 17q (0.6
became 1.6). No chromosomal regions reached potential
evidence for linkage with logACR in analyses of NDM–NDM
pairs (data not shown).
The four regions that provide strongest support for
linkage with logACR are summarized in Table 3. The
evidence supporting linkage on chromosome 5q was derived
in large proportion from DM–DM pairs and DM–NDM pairs
with a small contribution derived from NDM–NDM pairs.
The evidence supporting linkage on chromosome 7q was
derived from DM–DM pairs and DM–NDM pairs with no
evidence for linkage coming from NDM–NDM pairs. The
evidence supporting linkage on chromosome 21q is derived
almost exclusively from DM–DM pairs. The evidence
supporting linkage on chromosome 22q appears to be
derived primarily from DM–DM pairs and DM–NDM pairs;
a small contribution is also derived from NDM–NDM pairs.
There were 59 Caucasian families and four minority
families (one African-American and three Hispanic). To
examine the impact of these four minority families on the
Table 3 | Maximum LOD scores for linkage with urinary logACRa according to chromosomal location, type of relative pair, and
ethnicity of families
All families Caucasian families onlyb
Chromosome Location (cM) Marker DM pairs NDM pairs All pairs DM pairs NDM pairs All pairs
5 69 GATA67D03 1.2 0.5 2.6 1.7 0.6 3.4
7 172 GATA30D09B 2.2 0.0 3.1 1.6 0.0 2.3
21 15 GGAA3C07 2.5 0.0 2.1 2.6 0.0 2.3
22 33 GATA11B12 1.9 0.6 3.7 1.8 0.5 3.4
alogACR was adjusted: for age, gender, diabetes, diabetes duration, MAP and %IBW in the analysis of all relative pairs; for age, gender, diabetes duration, MAP and %IBW in
the analysis of DM–DM pairs; and for age, gender, MAP and %IBW in NDM–NDM pairs.
bExclusion of the four minority families reduced the families to 59, the DM–DM pairs to n=1257, the NDM–NDM pairs to n=1825, and all pairs to n=5458.
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Figure 1 | Genome scan for linkage with logACR (adjusted for relevant covariates) obtained with SOLAR multipoint linkage analysis in
diabetic relative pairs only (upper panel) and in all relative pairs (lower panel). Only chromosomes with nominal LODX1.2 are shown.
Chromosome 3 is included because the LOD at position 161 cM was 3.2 in our previous study in type I diabetes.18 Chromosomal positions
correspond to the Marshfield map. After adjustment of logACR for covariates (age, gender, diabetes, diabetes duration, %IBW and MAP), the
mean7s.d. of the residuals according to study group were 0.077.7 and 0.076.1 in diabetic relatives and all relatives, respectively. Estimates of
skewness and kurtosis were 0.8 and 0.08 in diabetic relatives and 0.9 and 1.3, in all relatives, respectively.
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linkage results, we repeated the analysis after excluding the
minority families. The nominal LOD changed significantly
for two of the four regions with the strongest linkage signals
in the analysis of all families (Table 3). The nominal LOD for
linkage with logACR on chromosome 5q increased signifi-
cantly in DM–DM pairs (1.2 became 1.7) and in all pairs (2.6
became 3.4). These increased LOD scores occurred despite
the reduced number of DM–DM pairs (from 1332 to 1257)
and all pairs (from 5656 to 5558) after the exclusion of
minority families. The evidence for linkage with logACR on
chromosome 7q declined significantly in DM–DM pairs (2.2
became 1.6) and in all pairs (3.1 became 2.3). The evidence
for linkage with logACR on 21p increased slightly, and
evidence on 22q decreased slightly. The contribution of
NDM–NDM pairs to the evidence for linkage on chromo-
some 5q and 22q remained minimal.
In order to examine the effect of ESRD on the linkage
results, the analyses were repeated with the ACR values
‘Winsorized’, so that the phenotypic value of ACR in those
with ESRD was reduced from 2500 to 800. An ACR value of
800 represents the 90th percentile of the distribution in
diabetic relatives. The effect of this change in ACR among
those with ESRD was minimal. The support for linkage
declined by 0.1, remained the same, or increased by 0.1 in
diabetic relatives. In all relatives, the support for linkage
declined by 0.4 on 5q and 0.3 on 22q in all families; in
Caucasian families, the decline was 0.3 on 5q and 0.2 on 22q.
Support for linkage on 7q and 21p was unchanged.
We have extended the variance components method
to model genotype-by-diabetes (GDM) interaction for
logACR values. First, the analyses of the total sample
provided no evidence for GDM on logACR. The difference
in genetic variances of logACR in diabetic (sDM7s.e.¼
3.4970.65) and nondiabetic (sNDM7s.e.¼ 2.4070.36) re-
latives was not statistically significant (P¼ 0.16), and the
genetic correlation (rG) between relative pairs discordant for
diabetes (rG(DM, NDM)7s.e.¼ 0.6470.29; P¼ 0.03) was not
statistically different from 1.00 (P¼ 0.12). Second, there was
no improvement in the strength of linkage support with the
chromosomal regions reported in Table 3 when the data were
subjected to a QTLDM interaction model (data not
shown). Thus, the GDM interaction analyses suggest that
the genetic determinants of variation in logACR are similar in
diabetic and nondiabetic relatives.
The linkage plots of linkage analysis of logACR for
chromosomes 22q, 5q, 7q and 21p together with nominal
and empirical P-values are shown in Figure 2. The locations
of the linkage peaks are very similar in DM–DM pairs as well
as in all pairs. The support for linkage in genetic regions on
22q, 5q and 7q was much stronger in all pairs than in the
subset that included only DM–DM pairs. Nominal P-values
for evidence for linkage in all relatives on 22q, 5q and 7q were
lower than empirical, indicating that the nominal P-values
may have slightly overstated the evidence for linkage to these
regions. In contrast, the support for linkage of logACR to
chromosome 21p in DM–DM pairs was stronger than in the
group of all pairs, despite the larger number of relative pairs
in the latter analysis.
The LOD-1 support intervals for the four chromosomal
regions are shown in Figure 2. The LOD-1 support interval on
chromosome 22q spans a genetic region of 11 cM, which
corresponds to 9.1 Mb on the physical map. The LOD-1
support interval in Caucasian families on chromosome 5q spans
a genetic region of 10 cM, which corresponds to 11.6 Mb on the
physical map. The LOD-1 support interval on chromosome 7q
spans a genetic region of 16 cM, which corresponds to 4.7 Mb
on the physical map. The LOD-1 support interval on
chromosome 21p spans a genetic region of 14 cM, which
corresponds to 6.1 Mb on the physical map.
DISCUSSION
Substantial literature has accumulated on the familial
aggregation of elevated urinary albumin excretion as the
main phenotype of diabetic nephropathy. However, the
genetic architecture underlying familial aggregation of this
phenotype remains unknown. The current study is the first to
search for chromosomal regions harboring genes controlling
variation in urinary albumin excretion in large, predomi-
nantly Caucasian families with type II diabetes. Using a
genome scan approach, we found evidence for linkage with
variation of urinary albumin excretion on chromosome 22q,
5q and 7q. The patterns of linkage results obtained in
DM–DM and in all relative pairs indicate that these
chromosomal regions harbor QTLs that control variation
in urinary albumin excretion in diabetic as well as in
nondiabetic relatives. An additional QTL on 21p may exert its
effect on urinary albumin excretion, but only in the presence
of diabetes.
To interpret the results of this study, some new aspects of
our investigation should be considered. First, previous
attempts to map susceptibility genes for diabetic nephropathy
in families defined nephropathy as overt proteinuria, a
discrete phenotype. In contrast, our effort was to identify
QTLs linked with variation in a cardinal quantitative
phenotype of diabetic nephropathy, urinary albumin excre-
tion. Second, by selecting large families that included many
members with and without type II diabetes, we were able to
test whether the genetic determinants of variation in urinary
albumin excretion are the same in diabetic as in nondiabetic
relatives. Third, the use of extended families and an analytic
approach that could use all family members gave us a
robustly powered sample of 5656 relative pairs.
The present study confirms the significant role of genetic
factors in controlling variation in urinary albumin excretion.
Our estimates of the heritability of urinary albumin
excretion, ranging from 0.20 to 0.39 in diabetic and
nondiabetic groups of relatives, are similar in magnitude to
heritability estimates reported previously.3–6
In this study, we found a high genetic correlation between
the urinary albumin excretion of diabetic and nondiabetic
relatives in pairs discordant for diabetes. Also, there was no
statistically significant difference in the genetic variances of
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urinary albumin excretion in diabetic and nondiabetic
relatives. These findings suggest that QTLs contributing to
variation in urinary albumin excretion in diabetic and
nondiabetics relatives are similar, as proposed in our previous
publications.4,7 This hypothesis is supported further by our
finding of strong evidence for linkage to variation of urinary
albumin excretion on three chromosomes in the genome
scan. The first genetic region is on chromosome 22q with a
peak at 36 cM. The second genetic region is on chromosome
7q with a peak at 169 cM. The third genetic region is on
chromosomal 5q with a peak at 69 cM. The evidence for this
genetic region became stronger when the four minority
families were excluded, suggesting that this region may
control variation in urinary albumin excretion primarily in
Caucasian families.
Although the support for linkage to these chromosomal
regions from the NDM–NDM relative pairs was minor and
that from the DM–DM and DM–NDM relative pairs was
major, we concluded that these three chromosomal regions
contain QTLs controlling variation in urinary albumin
excretion in diabetic as well as in nondiabetic individuals.
There are three reasons for our conclusion. First, the weak
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Figure 2 | Detailed genome scan plots of LOD for linkage with logACR on chromosome 22, 5, 7 and 21 for DM–DM pairs only (broken
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evidence for linkage in NDM–NDM relative pairs results
from the large proportion of pairs consisting of distant
relatives, a feature that effectively diminishes the power to
identify linkage in this subgroup alone. Second, the evidence
for linkage coming from the DM–NDM relative pairs
appeared to be true and it was only minimally influenced
by the high values of urinary albumin excretion assigned to
individuals with ESRD. Third, when GDM interaction was
incorporated in the analyses, there was no evidence of
different gene(s) that influence variation in urinary albumin
excretion values in diabetic and nondiabetic relatives.
The support for linkage of urinary albumin excretion to
chromosome 21p with a peak at 13 cM is in contrast with the
findings on chromosomes 5q, 7q and 22q. The evidence for
linkage came from the diabetic relative pairs and not at all
from the other subgroups. These results are consistent with
the possibility that this QTL controls variation in urinary
albumin excretion but only in the presence of exposure to
diabetes. However, owing to the lack of support for this
hypothesis from the test for QTLDM interaction and only
suggestive evidence for linkage, this hypothesis needs to be
tested further in different family collections.
The identities of the putative QTLs located in the
chromosomal regions linked to variation in urinary albumin
excretion in diabetic and nondiabetic relatives are unknown.
We compared the four regions to NCBI’s genome annotation
(GenBank build 35, version 1), found at http://
www.ncbi.nlm.nih.gov/. In the 9.1 Mb critical region on
22q, there are 115 known or highly probable genes, none
representing an obvious candidate. In the 4.7 Mb critical
region on 7q, there are 50 known or highly probable genes
and one, eNOS, is a strong candidate. Association of
polymorphisms in this gene with the risk of ESRD in
diabetic and nondiabetic individuals has been reported by
our group19 and by others.20–22 However, there are studies
that did not find any association.23–25 Finally, in the 11.6 Mb
critical region on 5q and the 6.1 Mb critical region on 21p,
there are 71 and 16 known or highly probable genes,
respectively, but no obvious candidates.
Only a few genome screens have been conducted in search
of chromosomal regions harboring susceptibility genes for
diabetic kidney disease. A genome scan was performed in
Pima Indian families using 93 diabetic sib-pairs concordant
for overt proteinuria.26 Three chromosomal regions were
identified with at least potential evidence for linkage with
diabetic nephropathy. Only one region provided evidence
that was sufficiently strong to be considered suggestive, a
region in proximity to our region on chromosome 7q
(LOD¼ 2.0 at 144 cM). The other regions in the Pima study
occurred on chromosome 3q (LOD¼ 1.5 at 181 cM) and on
chromosome 20p (LOD¼ 1.8 at 18 cM). A partial genome
scan was performed in 18 extended Turkish families with type
II diabetes.27 The investigators obtained strong evidence for
linkage with ‘proteinuria only’ or ‘proteinuria with micro-
albuminuria’ on chromosome 18q. Assuming a dominant
mode of inheritance in the Turkish families provided a
LOD¼ 6.6 at 110 cM, while assuming a recessive mode of
inheritance yielded a LOD¼ 2.2 at the same location.
A genome scan in search of regions linked with variation
in urinary albumin excretion was also conducted in 805 sib-
pair families collected by the Hypertension Genetic Epide-
miology Network.5 In the 1727 nondiabetic relative pairs in
that study, suggestive evidence for linkage was found on 19p
(LOD¼ 2.7 at 9 cM) and on 12q (LOD¼ 2.0 at 112 cM).
Weak evidence for linkage was found on 7q (LOD¼ 0.9) and
22q (LOD¼ 1.2) at locations corresponding to the two
chromosomal regions identified in our study.5 In the
Framingham Heart Study, which had 1497 nondiabetic
relative pairs, evidence for linkage with urinary albumin
excretion was found on chromosome 8q (LOD¼ 2.2 at
135 cM).6 In our previous report, based on 66 sib-pairs with
type I diabetes and discordance for diabetic nephropathy,
three candidate chromosomal regions were examined for
linkage. In that study, strong evidence for linkage was
observed on chromosome 3q (LOD¼ 3.2 at 161 cM).18 In the
present study, the evidence for linkage at the same location
was weak (LOD¼ 0.8 in diabetic pairs and LOD¼ 1.0 in all
pairs).
The results of our study support a hypothesis that genetic
predisposition to diabetic kidney disease is reflected in the
level of urinary albumin excretion, which is controlled by (at
least) four QTLs. In the absence of diabetes, three of them
determine where urinary albumin excretion falls within the
low and the high-normal range. With exposure to diabetes,
individuals with low levels of urinary albumin excretion
remain free of diabetic kidney disease whereas those with the
high-normal levels of urinary albumin excretion are at risk of
worsening to microalbuminuria and overt proteinuria.4,7 The
risk of the latter is influenced also by another locus specific to
diabetes exposure. The nature of abnormalities in the kidney
that determine the level of urinary albumin excretion and are
impacted by the QTLs is unknown. Two processes may be
influenced, the passage of serum proteins through the
glomerular filtration barrier, and reabsorption and degrada-
tion of these proteins by renal tubular cells.28
The main limitation of our study is the lack of precision
inherent in an assessment of urinary albumin excretion based
on a single ACR measurement. This would bias the results
toward the null hypothesis, reducing heritability estimates for
urinary ACR and reducing the evidence for linkage with
specific chromosomal regions. Moreover, a proportion of
family members were treated with angiotensin converting
enzyme (ACE) inhibitors. The reduction in urinary albumin
excretion by this treatment is expected to dampen variation
in urinary albumin excretion and bias the evidence for
linkage toward the null hypothesis. We examined the impact
of ACE inhibitor treatment, first by considering it as a
covariate in analyses of heritability, and second by sensitivity
analyses evaluating the effect of different reductions in
albumin excretion in those treated with ACE inhibitions
(data not shown). In both circumstances, the impact of
treatment with ACE inhibitors on LOD scores was insignificant.
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MATERIALS AND METHODS
Collection of families with type II diabetes
The families used for this study had been recruited previously for
the Joslin Study on the Genetics of Type 2 Diabetes.4,17 Briefly,
between 1993 and 2003, families were ascertained through probands
with type II diabetes and examined because the pattern of
occurrence of type II diabetes in family members was consistent
with an autosomal dominant mode of inheritance. An additional
selection criterion was the willingness of a large number of family
members (with and without diabetes) to participate in the study.
Using these criteria, 104 families were ascertained. The mean age at
diagnosis of type II diabetes for a family was ‘early’ in 46 families
(o35 years) and ‘middle-age’ in 68 (35–59 years). Of the families
selected for this study, 63 out of the 68 families with diagnosis in
‘middle-age’ represent common, type II diabetes. This set of families
included 59 European Caucasian families and four minority
families.
Examination of study participants
The Human Subjects Committee of the Joslin Diabetes Center
approved the study protocol and informed consent procedures.
After giving written consent to participate, family members living in
New England were examined by trained recruiters according to
previously described protocols.4,17 Subjects with impaired glucose
tolerance (IGT, n¼ 44) or gestational diabetes (GDM, n¼ 7) were
considered to be ‘diabetic’ with 0 years duration of diabetes.
Laboratory methods
Methods for measuring albumin and creatinine in a random urine
sample for determination of the ACR as an index of urinary albumin
excretion have been described previously.29,30 The value of ACR,
expressed in micrograms of albumin and milligrams of creatinine,
approximates the value of the corresponding albumin excretion
rate measured in a timed urine collection and expressed in
mg/min.30 Individuals with ESRD were assigned ACR values of
2500mg/mg. In order to approximate a normal distribution for
analyses, ACR values were transformed to the logarithm10 and
multiplied by 10 (logACR).
DNA extraction and genotyping
For all 900 examined members of the 63 families, DNA was
extracted from buffy-coat specimens using a standard phenol
chloroform protocol. A genome-wide scan was performed by the
NHLBI Mammalian Genotyping Service (http://research.marsh-
fieldclinic.org/genetics/) at the Marshfield Medical Research Foun-
dation. The panel of polymorphic markers (Screening Set 12)
consisted of 383 microsatellite markers spaced, on average, 9.1 cM
over 22 autosomes, with an average marker heterozygosity of 0.75.
Markers on sex chromosomes were not analyzed. Genotypes from
857 individuals were used in the reported analyses.
Statistical genetic analyses
Heritability of logACR was estimated by pedigree-based variance
components methods as implemented in the program SOLAR
(version 2.1. 4). Initially, logACR was adjusted for gender, age,
diabetes, diabetes duration, percent ideal body weight (%IBW),
MAP, and ACE inhibitor treatment. ACE inhibition did not
contribute significantly to the model and was omitted from the
adjustment of logACR for linkage analyses.
Pedigree-based variance component linkage analysis implemen-
ted in the program SOLAR was used to detect and localize QTLs
controlling variation in logACR.31,32 This approach has been shown
to be a powerful linkage analysis technique.32–34 Multipoint IBD
probabilities were calculated using the Markov chain Monte Carlo
methods implemented in the program Loki.35
Hypotheses were tested by likelihood ratio tests.36,37 Conversion
of the loge likelihoods to log10 yielded LOD scores. Empirical P-
values were based on simulations performed within SOLAR. A fully
informative marker unlinked to logACR was simulated, IBD scores
were estimated and linkage was analyzed. The distribution of LOD
scores from 10 000 or 50 000 simulations determined the empirical
P-value.
The estimation of heritability, and subsequently the evaluation of
linkage, incorporated a correction for ascertainment bias by
conditioning the likelihood for the family data on the phenotype
of the proband.38 To test for a GDM interaction on logACR in the
total sample, we extended the variance components approach by
examining the covariance between relative pairs under different
environments (i.e., DM and NDM relatives).39–41
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